蓝帆医疗
(002382)
| 流通市值：50.78亿 | | | 总市值：51.16亿 |
| 流通股本：10.00亿 | | | 总股本：10.07亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,654,357,096.34 | 3,005,595,271.23 | 1,454,848,751.06 | 4,927,074,862.96 |
| 营业收入 | 4,654,357,096.34 | 3,005,595,271.23 | 1,454,848,751.06 | 4,927,074,862.96 |
| 二、营业总成本 | 4,865,860,745.45 | 3,171,296,188.67 | 1,565,054,500.14 | 5,560,762,399.19 |
| 营业成本 | 3,855,177,720.39 | 2,518,802,038.74 | 1,241,542,057.87 | 4,320,997,000.86 |
| 税金及附加 | 32,131,109.21 | 22,102,491.17 | 11,131,314.3 | 36,326,311.28 |
| 销售费用 | 327,176,779.71 | 215,309,797.13 | 92,981,661.31 | 448,784,548.58 |
| 管理费用 | 240,582,619.09 | 155,269,672.88 | 74,006,244.44 | 339,645,819.56 |
| 研发费用 | 245,358,824.93 | 164,797,089.07 | 83,148,650.16 | 290,750,896.12 |
| 财务费用 | 165,433,692.12 | 95,015,099.68 | 62,244,572.06 | 124,257,822.79 |
| 其中:利息费用 | 206,191,854.31 | 131,491,787.83 | 56,115,310.47 | 182,251,713.64 |
| 其中:利息收入 | 20,810,832.04 | 13,881,122.23 | 6,080,089.17 | 26,262,438.77 |
| 加:公允价值变动收益 | -6,407.82 | 35,017.58 | -11,134.84 | 70,628,291.89 |
| 加:投资收益 | -7,721,768.26 | -7,232,200.88 | -4,316,708.96 | 14,407,812.67 |
| 资产处置收益 | -360,058.44 | 4,268.18 | 17,914.71 | -1,922,889.3 |
| 资产减值损失(新) | -15,345,677.01 | -12,508,886.92 | -13,675,578.49 | -72,256,103.95 |
| 信用减值损失(新) | -15,644,217.19 | -14,153,987.72 | -5,612,265.06 | -21,452,536.29 |
| 其他收益 | 22,020,165.74 | 18,277,090.11 | 13,401,212.06 | 39,436,849 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -228,561,612.09 | -181,279,617.09 | -120,402,309.66 | -604,846,112.21 |
| 加:营业外收入 | 18,764,827.6 | 18,253,090.46 | 18,406,650.21 | 9,752,997.54 |
| 减:营业外支出 | 4,525,038.97 | 3,354,531.53 | 1,578,493.83 | 27,517,195.82 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -214,321,823.46 | -166,381,058.16 | -103,574,153.28 | -622,610,310.49 |
| 减:所得税费用 | 12,601,948.52 | 2,076,580.86 | -4,835,216.48 | -54,249,823.72 |
| 六、净利润 | -226,923,771.98 | -168,457,639.02 | -98,738,936.8 | -568,360,486.77 |
| 持续经营净利润 | -226,923,771.98 | -168,457,639.02 | -98,738,936.8 | -568,360,486.77 |
| 归属于母公司股东的净利润 | -219,822,842.84 | -160,216,785.03 | -98,919,578.18 | -568,360,486.77 |
| 少数股东损益 | -7,100,929.14 | -8,240,853.99 | 180,641.38 | - |
| (一)基本每股收益 | -0.22 | -0.16 | -0.1 | -0.56 |
| (二)稀释每股收益 | -0.22 | -0.16 | -0.1 | -0.57 |
| 八、其他综合收益 | -32,979,291.84 | 9,581,758.86 | 24,882,816.8 | -53,005,695.89 |
| 归属于母公司股东的其他综合收益 | -25,647,369.57 | 8,697,743.72 | 24,519,372.49 | -53,005,695.89 |
| 九、综合收益总额 | -259,903,063.82 | -158,875,880.16 | -73,856,120 | -621,366,182.66 |
| 归属于母公司股东的综合收益总额 | -245,470,212.41 | -151,519,041.31 | -74,400,205.69 | -621,366,182.66 |
| 归属于少数股东的综合收益总额 | -14,432,851.41 | -7,356,838.85 | 544,085.69 | - |
| 公告日期 | 2024-10-30 | 2024-08-31 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |